UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Jun

    13

    UCB at EULAR 2024: Advancing Science for Rheumatic Conditions with High Unmet Needs

    Jun

    12

    UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

    Jun

    10

    Nicole Watson: Mom, Caregiver, and Best Friend, Shares How Her Daughter Emma, Diagnosed with Dravet Syndrome, Embraces Each Day with Love

    May

    31

    Go Behind The Mystery of Myasthenia Gravis On Myasthenia Gravis Awareness Month

    May

    23

    UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

    May

    10

    Moms Really Can Do It All - Meet Tracy: a Mom, Caregiver, Neuroscientist, and Advocate in the Rare Disease Community

    Apr

    12

    UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

    Apr

    11

    Our Leadership and Legacy in Epilepsy and Rare Syndromes

    Mar

    19

    Patty Fritz and Bianca Anderson Recognized by the Healthcare Businesswomen’s Association (HBA) as UCB Luminary and Rising Star

    Mar

    09

    First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis